Abstract
This third article in the series on antidepressants reviews the monoamine-oxidase inhibitors (MAOIs). A chance discovery by chest clinicians led to the development of this class of antidepressant medications. Although MAOIs are not the first choice in modern-day drug therapy due to significant side-effects and drug interactions, they have played an important role in the development of the pharmaceutical management of depression. Focusing on moclobemide for clarity, this article discusses the pharmacokinetics and pharmacodynamics of this class of drugs, before discussing precautions and prescribing in special populations. A summary of MAOIs currently in use and their alternative therapeutic indications is also presented.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call